Compare PRE & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRE | ZNTL |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | Hong Kong | United States |
| Employees | 285 | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 295.3M | 313.9M |
| IPO Year | N/A | 2020 |
| Metric | PRE | ZNTL |
|---|---|---|
| Price | $15.47 | $4.09 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $30.50 | $6.60 |
| AVG Volume (30 Days) | 176.0K | ★ 1.1M |
| Earning Date | 06-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $108.69 | N/A |
| Revenue Next Year | $58.68 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.15 | $1.13 |
| 52 Week High | $23.63 | $6.95 |
| Indicator | PRE | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 38.53 | 50.58 |
| Support Level | $14.67 | $3.75 |
| Resistance Level | $17.76 | $4.34 |
| Average True Range (ATR) | 1.28 | 0.30 |
| MACD | 0.03 | -0.06 |
| Stochastic Oscillator | 12.64 | 26.72 |
Prenetics Global Ltd is a health sciences company dedicated to advancing consumer health. The consumer initiative is led by IM8, one of the world's fastest-growing supplement brands; Europa, one of the sports distribution companies in the USA; and CircleDNA, a direct-to-consumer DNA testing company. As the first consumer healthcare company to establish a Bitcoin treasury with its initial approximately $20 million Bitcoin purchase and board-approved comprehensive Bitcoin plan of action, Prenetics is pioneering the intersection of healthcare innovation and digital asset adoption.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.